# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects

> **NCT06857253** · PHASE1 · COMPLETED · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** HRS-1301
- **DRUG:** HRS-1301 placebo

## Key facts

- **NCT ID:** NCT06857253
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-18
- **Primary completion:** 2025-08-11
- **Final completion:** 2025-08-11
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857253, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06857253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*